\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Methods}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{Genetic Estimation via Hardy–Weinberg Equilibrium}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Data\040Processing\040and\040Calculations}{section.2}% 4
\BOOKMARK [2][-]{subsection.2.3}{Incorporation\040of\040Variant\040Interpretation\040Guidelines}{section.2}% 5
\BOOKMARK [2][-]{subsection.2.4}{Toward\040a\040Bayesian\040Framework}{section.2}% 6
\BOOKMARK [2][-]{subsection.2.5}{Validation\040study}{section.2}% 7
\BOOKMARK [2][-]{subsection.2.6}{Validation\040Study}{section.2}% 8
\BOOKMARK [1][-]{section.3}{Results}{}% 9
\BOOKMARK [2][-]{subsection.3.1}{Part 1 – Initial Exploration in an Example Autosomal Dominant Gene: TNFAIP3}{section.3}% 10
\BOOKMARK [2][-]{subsection.3.2}{Part 2 – Validation Preparation of true known disease frequency with NFKB1}{section.3}% 11
\BOOKMARK [2][-]{subsection.3.3}{Part 3 – Validation Confirmation with NFKB1}{section.3}% 12
\BOOKMARK [2][-]{subsection.3.4}{Summary\040of\040Validation}{section.3}% 13
\BOOKMARK [1][-]{section.4}{Discussion}{}% 14
\BOOKMARK [1][-]{section.5}{Clinical\040Feature\040Reclassification\040and\040Informative\040Value\040Analysis}{}% 15
\BOOKMARK [1][-]{section.6}{Conclusions}{}% 16
\BOOKMARK [1][-]{section.7}{Future\040Directions}{}% 17
\BOOKMARK [1][-]{section.8}{Funding}{}% 18
\BOOKMARK [1][-]{section.9}{Acknowledgements}{}% 19
\BOOKMARK [1][-]{section.10}{Contributions}{}% 20
\BOOKMARK [1][-]{section.11}{Competing\040Interests}{}% 21
